Why Merck Missed the Mark

Why Merck Missed the Mark
S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold


Leave a Reply

Your email address will not be published. Required fields are marked *